ABBV vs AUNA

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

AUNA exhibits a Piotroski F-Score of 6/9, indicating stable financial health, but lacks an Altman Z-Score, limiting distress risk assessment. The stock appears undervalued with a current price of $5.66 versus a Graham Number of $12.0, suggesting defensive fair value, though growth metrics are weak with negative earnings and revenue growth. Profitability margins and ROE are positive, but high debt/equity and declining earnings raise concerns. Analysts recommend a 'buy' with a target price of $8.77, implying upside potential, but recent price volatility and deteriorating fundamentals temper bullishness.